Tern Plc cuts Board pay and introduces shareholder distribution policy

Tern plc

Tern Plc (LON:TERN), the investment company specialising in supporting high growth, early-stage, disruptive Internet of Things technology businesses, has announced a reduction in the fixed remuneration of Tern’s board and its executive management, together with a distribution commitment for when significant proceeds are received from exits of the Company’s investments.

As previously announced, the focus of the Board and Tern’s executive management team is on realisations and specifically seeking to maximise the value that can be realised from Tern’s portfolio companies and investments through successful exits from its investments at the appropriate time, ultimately seeking strong returns for shareholders.  At the same time the Company is maintaining strict control over operational costs and looking to make further savings where appropriate, in addition to the significant savings made in 2024 and the current financial year.

The Board have examined ways in which the operational costs of the Company can be further reduced, whilst aligning the interests of Tern’s Board and executive management with those of shareholders.  The Board, with the agreement of the executive management, have therefore resolved that:

·    Fixed remuneration reduction: From 1 November 2025 there will be a 50 per cent reduction in the salaries of the two Board directors, Jane McCracken and Iain Ross, and Tern’s executive managers Al Sisto and Bruce Leith.  This is expected to provide a saving of approximately £153,000 on an annualised basis.

·    Performance-aligned remuneration policy: The Board has adopted a remuneration policy whereby 12.5% of the net proceeds of any exit of the Company’s investments will be allocated to the executive team and Board, being those directly responsible for the Company’s capital allocation, strategy, and execution.

·    Shareholder distribution commitment: The Board has committed that shareholders will receive a distribution or capital return of at least 50% of the net proceeds received by the Company from the exit of any individual investment over £1 million (subject to the Company having sufficient distributable reserves and no legal or regulatory impediment to undertaking such an action).  

Commenting, Jane McCracken, Interim Non-Executive Chair of Tern, said: “We recognise that it is very important that management and shareholder interests are aligned, particularly during this capital-intensive phase of development of Tern’s investments.  The decision to reduce Board and executive management salaries by 50% will only have a modest financial impact on Tern, but coupling this with a fixed performance-based component of remuneration reflects our desire to signal a clear alignment of interests with shareholders.  This is not a discretionary bonus scheme, but a lean, outcome-driven policy designed to reflect the team’s scale of responsibility and the nature of our mandate.

“Our focus remains on realisations and we wish to give shareholders a clearer indication of what they can expect when we receive proceeds from exiting investments.  The Tern Board and management team are all working hard to deliver shareholder value and I look forward to providing further updates in due course.”

We’ll keep you in the loop!

Join 1,000's of investors who read our articles first

We don’t spam! Read our privacy policy for more info.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

Pharma faces a strategic turning point in AI adoption

AI in pharma is moving from operational support to strategic driver as companies prioritise messaging that delivers measurable prescriber impact.

Tern Plc updates position in Talking Medicines with new convertible loan notes

Tern Plc has received about £230,000 in new unsecured convertible loan notes from Talking Medicines after cancelling around £180,000 of short term loans provided over 2024 and 2025.

The real problem holding back connected vehicle programmes

Vehicle identity is fast becoming a core infrastructure challenge, and a new bottleneck for OEMs aiming to scale software-defined platforms.

Talking Medicines is building the AI layer beneath pharma marketing

Talking Medicines is shifting pharma marketing from content creation to data control, building the layer AI tools rely on to deliver credible, measurable clinical messaging.

A shift in how IoT is secured by default

KeyScaler 2025 transforms IoT security by automating trust across every device’s lifecycle, from onboarding to decommissioning, turning scalable connectivity and compliance into a built-in feature.

Turning employee sentiment into hard operational data

Workforce wellbeing is becoming a source of operational data, and the companies acting early are already reducing risk.

Search

Search